Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA releases stunning first images of Earth taken by the Artemis II astronauts - 2Does physics say that free will doesn't exist?
- 3Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- 4Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- 5Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- See tonight’s solar storm unfold across the world
- Some super-smart dogs can pick up new words just by eavesdropping
- UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- When does Spotify Wrapped come out? The music streamer says 'soon.'
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
